Ovarian cancer frequently begins in the ovaries but typically goes undetected until it is found in the pelvis and abdomen, making it difficult to treat and commonly fatal. Epithelial cancers account for 90% of ovarian cancers as many begin tumors grow in the tissue that surrounds the ovary (the epithelium). Most epithelial tumors are benign but the ones that are cancerous are commonly carcinomas. Epithelial cancers are the most dangerous as they are typically not diagnosed until a late stage. There are three types of ovarian cancer that differentiate depending on location of where it began: cancer than begins in the cells on the outside of the ovaries, cancer that begins in the egg-producing cells, and cancer that begins in the hormone-producing cells. Risk factors for ovarian cancer include inherited gene mutations, a family history of ovarian cancer, increasing age, and never being pregnant. Treatments for ovarian cancer most frequently include surgery and chemotherapy.
Epithelial Ovarian Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Epithelial Ovarian Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 4597 products for the study of Epithelial Ovarian Cancer that can be applied to Flow Cytometry, Chromatin Immunoprecipitation, Western Blot, Immunocytochemistry/Immunofluorescence, Chromatin Immunoprecipitation (ChIP), Immunohistochemistry from our catalog of antibodies and ELISA kits.
Epithelial Ovarian Cancer is also known as epithelial ovarian cancer, ovarian epithelial carcinoma, ovarian cancer, epithelial, ovarian epithelial cancer, eoc.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.